The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford supported by Parkinson’s UK with funds from The Monument Trust, one of the Sainsbury Family Charitable Trusts.
Established in February 2010, the OPDC brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Tuesday, 06 July 2021, 2pm to 3pm
Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire.
Becker S. et al, (2021), Neurol Sci
Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.
Okarmus J. et al, (2021), Stem Cell Reports, 16, 1510 - 1526
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Vijiaratnam N. et al, (2021), BMJ Open, 11
Revisiting dopamine-acetylcholine imbalance in Parkinson’s disease: glutamate co-transmission as an exciting partner in crime
CRAGG S. and Zhang Y-F., (2021), Neuron
Validation of α-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
Jiang C. et al, (2021), Mov Disord
Axonal Modulation of Striatal Dopamine Release by Local γ-Aminobutyric Acid (GABA) Signalling.
Roberts BM. et al, (2021), Cells, 10